Previously we showed that anti-Aβ peptide immunotherapy significantly attenuated Alzheimer's-like amyloid deposition in the central nervous system of aged canines. In this report we have characterized the changes that occurred in the humoral immune response over 2.4 years in canines immunized repeatedly with aggregated Aβ 1-42 (AN1792) formulated in alum adjuvant. We observed a rapid and robust induction of anti-Aβ antibody titers, which were associated with an anti-inflammatory T helper type 2 (Th2) response. The initial antibody response was against dominant linear epitope at the N-terminus region of the Aβ 1-42 peptide, which is identical to the one in humans and vervet monkeys. After multiple immunizations the antibody response drifted toward the elevation of antibodies that recognized conformational epitopes of assembled forms of Aβ and other types of amyloid. Our findings indicate that prolonged immunization results in distinctive temporal changes in antibody profiles, which may be important for other experimental and clinical settings.
Introduction
Alzheimer's disease (AD) is associated with progressive cognitive decline, neuronal loss and the accumulation of senile plaques and neurofibrillary tangles in affected regions of the brain (Braak and Braak, 1991; Mirra et al., 1991) . The amyloid beta peptide (Aβ) is a major component of senile plaques, and the original amyloid cascade hypothesis (Hardy and Higgins, 1992; Selkoe, 1996) proposed that the accumulation of amyloid plaques was the principal factor in AD pathogenesis, however the cascade hypothesis has evolved to include neurotoxic small soluble Aβ aggregates or oligomers (Golde et al., 2006; Lesne et al., 2006; Lue et al., 1999; Mucke et al., 2000; Walsh et al., 2002a; Walsh et al., 2002b) . Thus, therapeutic interventions currently being tested are targeted towards slowing production, accumulation or increasing clearance of pathological Aβ species (Selkoe, 2007; Selkoe and Schenk, 2003) .
Based on the success of immunotherapy in transgenic mice (Janus et al., 2000; Morgan et al., 2000; Petrushina et al., 2007; Schenk et al., 1999; Seabrook et al., 2007) , a clinical trial was initiated in AD patients who were immunized with aggregated Aβ42 (AN1792) formulated in QS-21 adjuvant. However, a subset of patients (6%) developed aseptic meningoencephalitis (Orgogozo et al., 2003; Schenk, 2002) , and the clinical trial was halted with patients receiving only 1-3 injections of AN1792 instead of 6 proposed in the Phase IIa protocol. Evaluation of the complete study cohort revealed limited cognitive benefits and "less worsening" of clinical outcome measures (Gilman et al., 2005) . In spite of the failure of AN1792 there is still considerable interest in active and passive immunotherapeutic approaches for AD (http:// www.clinicaltrials.gov/).
Aged dogs show a decline in learning and memory, which correlates with a progressive increase in Aβ pathology in the brain (Cummings et al., 1996; Head et al., 1998 Head et al., , 2000 Milgram et al., 2002 Milgram et al., , 1994 Selkoe, 1996) . We recently reported that immunizing aged beagles with aggregated Aβ 1-42 was associated with a significant reduction in brain Aβ (Head et al., 2008) , however, there were only minor improvements in learning and memory observed. Similar outcomes have now been confirmed in a recent study of 8 AD patients in the AN1792 trial who have come to autopsy. These patients showed significantly less Aβ plaque deposition, however, none of the immunized patients showed any slowing of dementia and all eventually progressed to end stage disease (Holmes et al., 2008) . E-mail address: vvasilev@uci.edu (V. Vasilevko). 1 DHC and EH contributed equally to this work.
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